CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes
While HPLC and mass spec make inroads into nontraditional markets, interest remains in molecular techniques that address the unique needs of clinicians and drug developers.